Prosthetic Heart Valve Devices And Equipment Market Report 2026

Prosthetic Heart Valve Devices And Equipment Market Overview

• Prosthetic Heart Valve Devices And Equipment market size has reached to $6.73 billion in 2025 • Expected to grow to $10.48 billion in 2030 at a compound annual growth rate (CAGR) of 9.9% • Growth Driver: Rising Prevalence Of Valvular Heart Disease Boosts Demand For Transcatheter Aortic Valve Replacement (TAVR) And Prosthetic Heart Valve Devices • Market Trend: Innovative Product Developments By Leading Companies In The Prosthetic Heart Valve Devices Market • North America was the largest region in 2025 and Western Europe is the fastest growing region.

What Is Covered Under Prosthetic Heart Valve Devices And Equipment Market?

Prosthetic heart valve devices and equipment are artificial heart valves that are implanted in the heart of a patient with valvular heart disease. They are used to regulate blood flow within the heart, improving circulation and overall heart function. These devices can be mechanical or biological, offering patients options based on their specific medical needs and conditions. The main types of prosthetic heart valve devices and equipment are transcatheter heart valve, tissue heart valve, and mechanical heart valve. Transcatheter aortic valve replacement is an invasive heart procedure to replace a thickened aortic valve that will not fully open. The product types are repair products, mitral valve repair devices, and tricuspid valve repair devices. The technologies involved in prosthetic heart valve devices and equipment are biological valves and decellularized valves that are used in various applications such as hospitals and ambulatory surgery centres.

What Is The Prosthetic Heart Valve Devices And Equipment Market Growth Forecast?

The prosthetic heart valve devices and equipment market size is expected to see strong growth in the next few years. It will grow to $10.48 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing preference for minimally invasive cardiac interventions, rising demand for longer-lasting valve implants, expansion of transcatheter valve indications, growing investments in structural heart disease treatment, increasing innovation in biological valve materials. Major trends in the forecast period include increasing adoption of transcatheter heart valve procedures, rising demand for tissue-based heart valves, growing use of minimally invasive valve repair systems, expansion of advanced valve durability technologies, enhanced focus on patient-specific valve solutions.

Global Prosthetic Heart Valve Devices And Equipment Market Segmentation

1) By Product Type: Repair Products, Mitral Valve Repair Devices, Tricuspid Valve Repair Devices 2) By Valve Type: Transcatheter Heart Valve, Tissue Heart Valve,  Mechanical Heart Valve 3) By Technology: Biological Valve, Decellularized Valve 4) By Application: Hospitals, Ambulatory Surgery Centres Subsegments: 1) By Repair Products: Transcatheter Mitral Valve Repair (TMVR) Devices, Transcatheter Tricuspid Valve Repair (TTVR) Devices 2) By Mitral Valve Repair Devices: Mitral Valve Repair Systems (MitraClip), Mitral Valve Annuloplasty Devices, Edge-to-Edge Repair Devices 3) By Tricuspid Valve Repair Devices: Tricuspid Valve Annuloplasty Devices, Tricuspid Valve Repair Systems

What Is The Driver Of The Prosthetic Heart Valve Devices And Equipment Market?

The rising prevalence of valvular heart disease has driven the need for transcatheter aortic valve replacement (TAVR) procedures, thus driving the prosthetic heart valve devices and equipment market. TAVR is a minimally-invasive surgical procedure done to cure aortic stenosis which is a valvular heart disease that affects the aortic valve of the heart. Aortic stenosis affects the aortic valve by hardening it, thus not allowing blood to properly flow through it and TAVR is used to replace this defective aortic valve with a transcatheter valve. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, over 695,000 people in the US died from heart disease, accounting for one out of every five deaths. As the rate of occurrence of valvular heart diseases rises, the number of TAVR procedures done can be expected to increase which also increases the demand for transcatheter valves, thus driving the market going forward.

Key Players In The Global Prosthetic Heart Valve Devices And Equipment Market

Major companies operating in the prosthetic heart valve devices and equipment market are Boston Scientific Corporation, Edwards Lifesciences, Medtronic plc, LivaNova plc, Abbott Laboratories, Jenavalve Technology Inc., Lepu Medical Technology, Cryolife Inc., Neovasc Inc., Braile Biomedica, Colibri Heart Valve, TTK Healthcare Ltd., Medical Technology Est., Micro Interventional Devices Inc., Well Health Technologies, On-X Life Technologies Inc., Meril Life Sciences Pvt. Ltd., Sorin Group, Commonwealth Edison Company, Cardiac Dimensions Inc., CardioSolutions Inc., Leman Cardiovascular, MitralSolutions Inc., Thubrikar Aortic Valve Inc., LifeNet Health Inc., Xeltis AG, Transcatheter Technologies GmbH, Venus Medtech (Hangzhou) Inc., MValve Technologies Ltd., MVRx Inc., NaviGate Cardiac Structures Inc., Pulmonx Corporation, Tendyne Holdings Inc., ValveXchange Inc., Vascutek Ltd., XpandOrtho Inc., Zhejiang A&F Medical Co. Ltd.

Global Prosthetic Heart Valve Devices And Equipment Market Trends and Insights

Major companies operating in the prosthetic heart valve devices and equipment market are developing tricuspid valve replacement systems to address the growing demand for effective treatments for tricuspid valve disease, improve patient outcomes, and reduce complications associated with traditional heart valve surgeries. Tricuspid valve replacement systems refer to medical devices designed to replace the tricuspid valve in the heart, which controls blood flow between the right atrium and right ventricle. For instance, in October 2023, Edwards Lifesciences, a US-based technology company received CE Mark approval for the EVOQUE system, making it the world's first transcatheter valve replacement therapy approved for the treatment of tricuspid regurgitation (TR). The EVOQUE valve features a nitinol self-expanding frame and tissue leaflets made from bovine pericardial tissue. It is designed to be delivered through a low-profile transfemoral 28-French system and will be available in three sizes.

What Are Latest Mergers And Acquisitions In The Prosthetic Heart Valve Devices And Equipment Market?

In July 2024, Edwards Lifesciences, a US-based provider of structural heart devices and critical care monitoring technologies, acquired JenaValve Technology, Inc. and Endotronix, Inc. for US$ 1.2 billion. With this acquisition, Edwards intends to expand its transcatheter valve portfolio to include aortic regurgitation and add heart failure management capabilities. JenaValve Technology, Inc. is a US-based company developing a transcatheter heart valve system (Trilogy) for aortic regurgitation, and Endotronix, Inc. is a US-based medical technology firm that develops implantable pulmonary artery pressure sensors for heart failure patients.

Regional Outlook

North America was the largest region in global prosthetic heart valve devices and equipment market in 2025. Western Europe was the second-largest region in prosthetic heart valve devices and equipment market. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

What Defines the Prosthetic Heart Valve Devices And Equipment Market?

The prosthetic heart valve devices and equipment market consist of sales of mechanical heart valves, transcatheter heart valves, and tissue heart valves that are used for heart patients. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.